Abstract | Emerging evidence points to a strong association between the gut microbiota and the risk, development and progression of gastrointestinal cancers such as colorectal cancer (CRC) and hepatocellular carcinoma (HCC). Bile acids, produced in the liver, are metabolized by enzymes derived from intestinal bacteria and are critically important for maintaining a healthy gut microbiota, balanced lipid and carbohydrate metabolism, insulin sensitivity and innate immunity. Given the complexity of bile acid signalling and the direct biochemical interactions between the gut microbiota and the host, a systems biology perspective is required to understand the liver-bile acid-microbiota axis and its role in gastrointestinal carcinogenesis to reverse the microbiota-mediated alterations in bile acid metabolism that occur in disease states. An examination of recent research progress in this area is urgently needed. In this Review, we discuss the mechanistic links between bile acids and gastrointestinal carcinogenesis in CRC and HCC, which involve two major bile acid-sensing receptors, farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (TGR5). We also highlight the strategies and cutting-edge technologies to target gut-microbiota-dependent alterations in bile acid metabolism in the context of cancer therapy.
1
. Cancers of the gastrointestinal tract repre sent one of the leading causes of mortality worldwide 2 .
In the USA, colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancerrelated deaths 3 . Hepatocellular carcinoma (HCC), the most common primary cancer of the liver, is the fifth most common cancer in men (~554,000 cases) and the ninth most common cancer in women (~228,000 cases) globally 4 , and it is the third leading cause of cancer related deaths 5 . In the USA, it is estimated that there will be ~135,430 new cases of CRC and ~40,710 new cases of liver cancer (~90% of primary liver cancers in the USA are HCC) in 2017 (REFS 2, 3) .
The human gastrointestinal tract is colonized by a diverse range of symbiotic bacteria and other microorgan isms that are collectively known as the gut microbiota 6, 7 . The host genome and microbiome (that is, the collective genomes of the gut microbiota) coproduce a large array of metabolites that serve as important sig nalling factors and energy substrates. These metabolites include bile acids such as deoxycholic acid (DCA) and lithocholic acid (LCA), which are involved in digestive processes or act as aetiological agents and mediators of pathogenic processes 8, 9 ; choline, which is involved in the transportation of lipids, methylation reactions and neuro transmitter synthesis 10 ; neurotransmitters such as glycine, glutamate, and GABA 11 ; and shortchain fatty acids (SCFAs) such as acetate and butyrate, which shape the composition of the gut microbiota and therefore influence colon physiology and serve as energy sources for host cells and the intestinal microbiota 12, 13 . The crosstalk between this dynamic set of small molecule metabolites -known as the metabolome -and the host modulates the immune system, regulates metabolic phenotypes and influences risk factors for disease and response to therapy 14, 15 . Mounting evidence obtained from studies in humans and animal models has revealed the tumour promoting effects of the gut microbiota and has therefore linked the microbiota to gastrointestinal carcino genesis [16] [17] [18] . An example of bacterial pathogeninduced carcino genesis is Helicobacter pyloriinduced gastric cancer 19 . H. pylori triggers gastric atrophy and hypochlorhydria through the secretion of a virulence factor, cytotoxin associated protein A (CagA), which renders the stomach susceptible to the overgrowth of other pHsensitive bacterial species, such as Acinetobacter, and subse quently leads to an increase in the rate that bacteria convert dietary nitrates into carcinogens 20 . Another example is gallbladder cancer, which is associated with chronic infection with Salmonella enterica subsp. enter ica serovar Typhi and Salmonella enterica subsp. enterica serovar Paratyphi 21 . S. Typhi has a mutagenic effect on the gallbladder epithelium that results from the metabolism of bile salts into carcinogenic secondary bile acids and other genotoxins 22 . In addition, enterotoxigenic bacteria, such as Fusobacterium nucleatum, Escherichia coli NC101 and Bacteroides fragilis promote CRC development 23, 24 . These bacteria can either induce chronic inflammation and increase reactive oxygen species (ROS)mediated genotoxicity or directly pro mote carcinogenesis by secreting toxins that induce DNA damage responses, such as the adhesin protein FadA from F. nucleatum and polyketide synthases from E. coli 25 . Indeed, suppression of intestinal bacteria with antibiotic treatment in mice reduced the development of colon and liver cancer 17, 26 . Among the diverse array of endogenous metabo lites derived from host-gut microbiota co metabolism, bile acids are currently receiving increased attention owing to their known tumourpromoting proper ties 17, [27] [28] [29] . Bile acids are synthesized in the liver and have direct or indirect antimicrobial effects; bile acids can modu late the composition of the microbiota, which in turn regulates the size and composition of the bile acid pool. Bile acids are recognized as endogenous ligands 30, 31 for a number of ligandactivated transcrip tion factors of the nuclear hormone receptor family, including the farnesoid X receptor (FXR, also known as NR1H4) 30 , G protein coupled bile acid receptor 1 (TGR5, also known as GPBAR1) 32, 33 , pregnane X recep tor (PXR, also known as NR1I2) 34 , vitamin D 3 receptor (VDR) 35 and constitutive androstane receptor (CAR, also known as NR1I3) 34 . Accumulating evidence demonstrates a crucial role for bile acids in gastro intestinal carcinogenesis. The gut bacterial metabolite DCA has been shown to promote the development of obesityassociated HCC in a mouse model pre treated with 7,12 dimethylbenzanthracene (DMBA) 17 . In addition, exposure of hepatocytes to DCA induced the expression of inflammatory genes, which is closely associated with the development of cancer 36 .
In the past few years, research interest in the role of bile acid-microbiota crosstalk in gastrointestinal cancer has surged. In this Review, we discuss the bio synthesis, metabolism and transport of bile acids, with a focus on biosynthetic pathways, amidation and key bile acid transporters. We also highlight the mech anistic links between the gut microbiota, bile acids and gastro intestinal carcinogenesis through the major bile acidsensing receptors, FXR, TGR5, PXR, CAR and VDR. Finally, the mechanistic roles of bile acids and the microbiota in the development of HCC and CRC are reviewed, and opportunities for the control and prevention of gastrointestinal cancers by targeting the liver-bile acid-microbiota metabolic axis are presented.
Enterohepatic circulation of bile acids
The processes of bile acid synthesis, transport, metabo lism and regulation have been extensively reviewed elsewhere 33, 37, 38 . In this section, we therefore provide an overview of bile acid enterohepatic circulation to provide context for later discussion of the role of bile acids in gastrointestinal inflammation and carcinogenesis.
Bile acid synthesis, transport and metabolism. Bile acids are synthesized in hepatocytes via cytochrome P450 (CYP)mediated oxidation of cholesterol, which can occur through two biosynthetic pathways; the 'clas sical' and 'alternative' pathways 39 (FIG. 1) . The 'classical' pathway produces the primary bile acids cholic acid (CA) and chenodeoxycholic acid (CDCA) through the enzymatic actions of three cholesterol hydroxylase enzymes: CYP7A1, CYP8B1, and CYP27A1 (REF. 32 ). The 'alternative' pathway yields CDCA via the hydroxy lation of the cholesterol side chain by CYP27A1, fol lowed by 7αhydroxylation of 27hydroxycholesterol and other oxysterols by CYP7B1 (REF. 32) .
Following the conjugation of the primary bile acids CA and CDCA to either taurine (predominantly in mice) or glycine (mainly in humans) by bile acyl CoA synthetase (BACS) and bile acidCoA:amino acid Nacyltransferase (BAAT) to form taurocholic acid (TCA), taurochenodeoxycholic acid (TCDCA), glyco cholic acid (GCA) and glycochenodeoxycholic acid (GCDCA), primary bile acids are secreted from the liver into the bile canaliculus via the canalicular bile salt export pump (BSEP, also known as ABCB11) 33 . Concurrently, sulfated (catalysed by enzymes such as sulfotransferase 2A1 (SULT2A1)) or glucuronidated (catalysed by UDPglucuronosyltransferase (UGT) enzymes) bile acids are amidated with either taurine or glycine and are secreted from the liver into the bile via multidrug resistanceassociated protein 2 (MRP2, also known as ABCC2) (REFS 40, 41) . During cholesta sis 42 (that is, when the flow of bile from the liver is slowed or blocked), excessive amounts of hepatic bile acids and bilirubin can be excreted into the systemic
Key points
• Bile acids are critical components of the gastrointestinal tract that link the gut microbiota to hepatic and intestinal metabolism and therefore influence gastrointestinal motility, intestinal permeability and carcinogenesis • The gut microbiota regulates bile acid production and signalling via the biotransformation of intestinal bile acids to unconjugated and secondary forms that readily activate bile acid receptors • Bile acids are ligands for the G protein-coupled bile acid receptor 1 (TGR5) and for the nuclear hormone receptor farnesoid X receptor (FXR) • The profiles of bile acids and gut microbiota influence each other; bile acids can modulate microbiota composition, which in turn regulates the size and composition of the bile acid pool • Disruption of bile acid-microbiota crosstalk promotes inflammation and a gastrointestinal disease phenotype, which can contribute to the development of gastrointestinal cancers, including colorectal cancer and hepatocellular carcinoma • The modulation of gut microbiota and bile acid profiles holds promise as a novel therapeutic approach for the treatment of gastrointestinal cancers and represents the next frontier for gastrointestinal cancer research Figure 1 | Bile acid biosynthesis, transport and metabolism. The most abundant bile acids (BAs) in mammals include the primary BAs cholic acid (CA) and chenodeoxycholic acid (CDCA) and the secondary BAs deoxycholic acid (DCA) and lithocholic acid (LCA). BAs are synthesized in hepatocytes via the cytochrome P450 (CYP)-mediated oxidation of cholesterol, which occurs in the 'classical' and 'alternative' pathways. The 'classical' pathway is initiated by CYP7A1 and produces CA and CDCA through the subsequent action of CYP8B1 and CYP27A1. The 'alternative' pathway is initiated by CYP27A1 and yields CDCA via CYP7B1. CYP8B1 expression determines the CA:CDCA ratio by promoting CA biosynthesis. In the rodent liver, the majority of CDCA is converted to α-muricholic acid (α-MCA) and β-MCA. In the pig liver, CDCA is primarily converted to hyocholic acid (HCA) 54 via C-6α-hydroxylation by CYP3A4 (REFS 54, 55) . However, in humans, CDCA is not converted, and the primary BAs are CA and CDCA. In hepatocytes, most BAs are conjugated to glycine (glyco-, G) or taurine (tauro-, T) through the action of bile acid-CoA synthetase (BACS) and bile acid-CoA:amino acid N-acyltransferase (BAAT) before their secretion into bile via the bile salt export pump (BSEP). Differences in the types of conjugated BAs produced exist between human and rodents; the dominant BAs in humans and rodents are listed in the solid and dashed rectangles, respectively. Simultaneously, sulfated (sulfo-) or glucuronidated (glucurono-) BAs are produced by the liver via sulfotransferases (SULTs) and UDP-glucuronosyltransferases (UGTs), conjugated to glycine or taurine and taken up by the multidrug resistance-associated protein 2 (MRP2) to be excreted into the bile. In the intestine, microbial enzymes from gut bacteria (dashed arrows) metabolize BAs
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; glyco-conjugated and tauro-conjugated CA and CDCA are deconjugated via bile salt hydrolases (BSH) and 7α-dehydroxylated to form secondary BAs (DCA and LCA). T α-MCA and T β-MCA are deconjugated via BSH to form α-MCA and β-MCA. β-MCA is C-6 epimerized to form ω-MCA, and then ω-MCA is 7α-dehydroxylated to form hyodeoxycholic acid (HDCA) 55 . CDCA is transformed into ursodeoxycholic acid (UDCA) by the hydroxysteroid dehydrogenase (HSDH) 199 . Glucurono-and sulfo-conjugated BAs are mainly excreted into urine by MRP2 (REFS 200, 201) . The main bacterial genera of the gut microbiota involved in BA metabolism include Bacteroides, Clostridium, Lactobacillus, Bifidobacterium and Listeria in BA deconjugation; Bacteroides, Eubacterium, Clostridium, Escherichia, Eggerthella, Eubacterium, Peptostreptococcus and Ruminococcus in the oxidation and epimerization of hydroxyl groups at C3, C7 and C12; Clostridium and Eubacterium in 7-dehydroxylation; Bacteroides, Eubacterium and Lactobacillus in esterification; and Clostridium, Fusobacterium, Peptococcus and Pseudomonas in desulfatation 51, 60 . At the terminal ileum, most unconjugated BAs (including CA, CDCA, DCA, UDCA, HDCA, α-MCA, β-MCA, and ω-MCA) are reabsorbed by the apical sodium-dependent BA transporter (ASBT) into enterocytes and secreted into the portal circulation via the basolateral BA transporters organic solute transporter subunit α (OSTα), OSTβ, MRP2 and MRP3. BAs are then taken up by sodium/taurocholate cotransporting polypeptide (NTCP) and organic anion-transporting polypeptide 1 (OATP1) into hepatocytes. Hepatic MRP3, MRP4 and the OSTα-OSTβ complex also provide alternative excretion routes for BAs into the systemic circulation 40, 41 . 40, 41 . In the post prandial state, the gallbladder contracts and releases bile acids (in the form of mixed micelles containing bile acids, cholesterol and phospholipids) into the intesti nal lumen 43 , thus facilitating the emulsification and absorption of lipids in the small intestine 44 . Following lipid absorption, both conjugated and unconjugated bile acids are reabsorbed in the distal ileum by the apical sodiumdependent bile acid transporter (ASBT, also known as SLC10A2), which is located in the brush border (that is, the apical microvillus membrane of small intestinal epithelial cells) 37, 45 . These bile acids are then bound to the ileal bile acidbinding protein (IBABP), which mediates bile acid transport across the enterocyte to the basolateral membrane, where the enteric OSTα-OSTβ complex facilitates transport into the portal vein 46 . Bile acids are the endogenous ligands for the nuclear receptor FXR. Activation of ileal FXR by unconju gated bile acids downregulates the expression of ASBT and induces the expression of IBABP and of OSTα and OSTβ 47 . Ileal bile acids are recycled to the liver, where they are taken up primarily by the sodium/ taurocholate cotransporting polypeptide (NTCP, also known as SLC10A1) and to a lesser extent by OATP1 and OATP4 (REFS 22, 23) , and their synthesis is negatively regulated by nuclear FXR through a feedback mechanism to limit the accumulation of bile acids in the liver 48 . In humans, NTCP largely accounts for the uptake of conjugated bile acids (>80%) 49 , whereas the members of the OATP family efficiently transport unconjugated or sulfated bile acids 50 to the liver. The cyclic process by which bile acids are secreted from the liver into the intestine, reabsorbed in the ileum and returned to the liver via the portal vein is termed enterohepatic circulation. Optimally, a bile acid pool of about 3 g (~90-95%) is recycled between the gut and the liver approximately eight times per day, with only ~0.2-0.6 g of de novo synthesized bile acids being produced per day to maintain a stable pool of bile acids 37, 51 .
Signalling regulation of bile acid synthesis and transport. Hepatic FXR is the primary regulator of bile acid biosynthesis and enterohepatic circulation. Under normal physiological conditions, the activity of hepatic FXR regulates bile acid levels in the biliary tree and intestine, while limiting bile acid accumulation in the liver (FIG. 2a) . Normal intestinal FXR activity maintains an efflux of bile acids back into the portal vein and a controlled reuptake of bile acids into enterocytes that limits intracellular bile acid levels 52 . Activation of intes tinal FXR upregulates the expression of fibroblast growth factor 15 (FGF15) in mice and its orthologue FGF19 in humans, which inhibit bile acid synthesis in hepatocytes via the activation of hepatic fibroblast growth factor receptor 4 (FGFR4) 47 .
Speciesspecific differences in bile acid synthesis, transport and metabolism occur, particularly with respect to the composition of the bile acid pool. In the rodent liver, the majority of CDCA is converted to αmuricholic acid (αMCA) through the action of a 6β hydroxylase, which can be further converted to βMCA by epimeriza tion of the 7αhydroxyl (OH) group of αMCA to 7βOH 53 . Conversely, in the pig, CDCA is predomin antly converted to hyocholic acid (HCA) 54 in liver via C6αhydroxylation by CYP3A4 (REFS 54, 55) ; however, some studies report that HCA might be formed from αMCA in the intestine 56 . The majority of human hepatic bile acids tend to be glycineconjugated, whereas a higher proportion of rodent bile acids are taurine conjugated 33 . A study that compared serum bile acid composition between mice, rats and humans reported that unconjug ated bile acids account for the majority of total bile acids in mice and rats (84% and 92%, respectively), including CA (24-50%) and MCAs (22-43%); however, glycine conjugated bile acids (42%) were most abundant in human serum, followed by DCA (19%), CA (16%) and CDCA (15%) 57 . In mice, taurineamidated βMCA (T βMCA) antagonizes FXR signalling in the intestine and, when present at low concentrations in the gut, creates a more hydrophobic bile acid profile that activates intestinal FXR 58 . Inhibiting intestinal FXR by T βMCA has been shown to downregulate FGF15 in mice and induce FGFR4dependent activation of CYP7A1 via the inhibition of JUN transcriptional activity 59 , leading to increased hepatic bile acid synthesis.
Signalling by bile acids
The ability of the gut microbiota to biotransform intes tinal bile acids into their unconjugated forms is central to the metabolic homeostasis of the gastrointestinal tract. These unconjugated bile acids can activate bile acid signalling receptors such as FXR, PXR, CAR, VDR and TGR5 (REFS 32, 33 51, 60 . Anaerobic intestinal bacteria of the genera Bacteroides, Eubacter ium and Clostridium deconjugate taurine conjugated and glycineconjugated bile acids to their respective unconju gated free forms through the action of bile salt hydrolase (BSH) 38 . Subsequently, anaerobes of the gen era Bacter oides, Clostridium, Eubacterium, Lacto bacillus and Escheri chia convert the unconjugated primary bile acids CDCA and CA into the secondary bile acids LCA and DCA through 7αdehydroxylation by CYP7A1 (REF. 51 ). The majority of CA, CDCA, DCA and LCA are then reabsorbed in the intestine and transported back to the liver, whereas most of the LCA is excreted in faeces 51 . , which results in reduced fibroblast growth factor 19 (FGF19)-FGF receptor 4 (FGFR4) signalling, the downregulation of intestinal bile acid-binding protein (IBABP) and the BA efflux transporters organic solute transporter subunit α (OSTα) and OSTβ 52, 203 and the upregulation of the apical sodium-dependent BA transporter (ASBT). Reduced expression of the IBABP carrier protein results in a reduction in the transfer of BAs across the enterocyte to the OSTα-OSTβ efflux complex for entry into the portal vein, thus disrupting enterohepatic circulation. The combination of these events permits increased influx of BAs into the enterocyte and prevention of BA efflux back into the portal vein. Collectively, the increased influx and decreased efflux of BAs might increase inflammation in the intestinal mucosa 47 . Diminished signalling via the FGF19-FGFR4 axis also increases BA synthesis in the liver via reduced activation of the JUN-extracellularsignal-regulated kinase (ERK)-cytochrome P450 7A1 (CYP7A1) axis [204] [205] [206] . During hepatic inflammation, which can be caused by bile acid perturbation of hepatocyte membranes, the subsequent activation of pro-inflammatory pathways activate nuclear factor kappa-B (NF-κB), which inhibits the transcription of hepatic FXR and prevents the subsequent activation of small heterodimer partner (SHP). Activated SHP inhibits the synthesis of the rate-limiting enzyme for BA synthesis, CYP7A1; therefore, decreased FXR expression promotes increased BA synthesis via the inactivation of SHP and decreased CYP7A1 levels in combination with an increased influx of BAs 96 because OSTα, OSTβ, multidrug resistance-associated protein 3 (MRP3) and MRP4 and all of the cannicular transporters (depicted in green ovals) are under the transcriptional control of FXR 96 . NF-κB-dependent inhibition of FXR transcription also leads to the decreased expression of sodium/ taurocholate co-transporting polypeptide (NTCP), which is involved in BA influx. However, multi-specific organic anion transporters (OATPs) are not affected by FXR 207 . FXR also controls BA detoxification; decreased transcription of FXR leads to decreased expression of peroxisome proliferator-activated receptor α (PPARα) and its target genes, which encode cytochrome P450 enzymes (CYPs), sulfotransferases (SULTs) and UDP-glucuronosyl transferases (UGTs) 203 . Decreased PPARα expression also induces additional decreases in the expression of the multidrug resistance protein 2 (MDR2), MDR3, MRP3 and MRP4 transporters. Under these conditions, both cholestasis and inflammation are intensified, which can lead to the development of liver cancer. Cholestasis causes inflammation via various mechanisms, leading to the upregulation and activation of NF-κB, which then binds directly to the FXR promoter to inhibit its transcription 84 . ABCG, ATP-binding cassette subfamily G; AE2, anion exchange protein 2; Bili-glu, bilirubin glucuronide; BSEP, bile salt export pump; HCO 3 − , bicarbonate; PC, phosphatidylcholine.
Lithogenic diet
A diet designed to increase the likelihood of stone formation, particularly gallstones.
Bile acids, FXR and TGR5. Unconjugated bile acids (such as CDCA, LCA, DCA and CA) act as high affinity ligand agonists of FXR [61] [62] [63] [64] [65] . Many in vitro stud ies in human liver and colon cell lines or in monkey or human cell lines that were transfected to overexpress human FXR have consistently shown a rank order for the ability of bile acids to activate FXR: CDCA has the greatest FXRactivating potential, followed by DCA, LCA and finally CA. However, an in vivo mouse study indicated that this rank order might be different under physiological, nonhepatotoxic conditions 64 ; the repres sion of the FXR target gene Cyp7a1 at a bile acid dose of 0.1% of their dietary intake indicated that DCA and urso deoxycholic acid (UDCA) activated FXR to equal extents, followed by CA, CDCA and finally LCA. Conversely, at a bile acid dose of 0.3%, UDCA was the most potent FXR activator, followed by DCA, CDCA, CA and finally LCA. Thus, at increased doses of bile acid, CDCA is a stronger FXR activator than CA. Although there is some controversy regarding the rank order of the FXRactivating potentials of bile acids between studies carried out in vitro and in vivo, there is a consensus that unconjugated bile acids have greater potential to activate FXR than conjugated bile acids 35, 65, 66 . TGR5, a bile acidspecific G proteincoupled recep tor (GPCR) that is ubiquitously expressed in humans and animals, activates various intracellular signalling pathways upon interaction with bile acids 67 . In vitro studies have shown that the rank order of bile acids for activating TGR5 is LCA (EC 50 (concentration of a drug that gives halfmaximal response) = 35 ± 5 nM), DCA (EC 50 = 575 ± 75 nM), CDCA (EC 50 = 4.00 ± 0.66 μM) and finally CA (EC 50 >10 μM) for unconjugated bile acids 68 . The rank order of both conjugated and unconjugated bile acids for activating TGR5 in Chinese hamster ovary cells transfected with human TGR5 has also been found to be taurolithocholic acid (TLCA), followed by LCA, GLCA, TDCA, DCA, GDCA, TCDCA, CDCA, GCDCA, TCA, CA and finally GCA 69 . Interestingly, the microbiotainduced secondary bile acids LCA and DCA and their conjugated forms were the strongest activ ators of TGR5 (REF. 69 ). Thus, these data infer that the gut microbiota can potentiate bile acid signalling through both bile acid signalling receptors, TGR5 and FXR.
Bile acids, PXR, CAR and VDR. PXR is primarily expressed in the liver and intestine, whereas CAR is pri marily expressed in hepatic tissues 34 . Both receptors are principal regulators of drug metabolism in the liver 70 . PXR activates the bile acid hydroxylation enzymes CYP3A and CYP2B, the bile acidconjugation enzy mes SULT2A1 and UGTs, the canalicular transporter MRP2 and the baso lateral transporter OATP2 . CAR also activ ates CYP3A, CYP2B and SULTs 73 . CAR and PXR might have a synergistic role in maintaining bile acid homeostasis in vivo, presumably through the combined induction of CYP3A4 and SULT2A1 (REF. 74 ), as evi denced by the observation that the combined loss of both receptors aggravated LCAinduced liver damage in mice 75, 76 . PXRdependent activation of intestinal FGF19 occurred only in colon cancer cells and not in normal intestinal crypt cells, and therefore PXR has been associ ated with the promotion of colon tumour growth 77 . Interestingly, Pxr −/− mice fed a lithogenic diet had a higher susceptibility to the development of cholesterol gallstones than wildtype mice owing to decreased Cyp7a1 expres sion, reduced biliary bile acid secretion and higher intes tinal FGF15 expression caused by increased activation of enteric FXR 78 . In addition, LCA activates PXR and indirectly activates CAR, which inhibits CYP7A1 tran scription by interacting with hepatocyte nuclear factor 4 alpha (HNF4α) 51 . VDR is primarily activated by 1α,25dihydroxy vita min D 3 , the biologically active form of vitamin D, and functions as a ligandregulated transcription factor that is highly expressed in the large intestine, particularly in immune cells 35 . The activation of VDR directly inter feres with dendritic cell differentiation and the produc tion of proinflammatory cytokines 35 . VDR primarily functions as an intestinal bile acid sensor that can be activated by LCA to induce the expression of CYP3A and SULT2A1 and therefore protect the gut from bile acid toxicity 79 . In addition, VDR induced Asbt expres sion in male Sprague-Dawley rats, which increased ileal bile acid transport 80 . It was reported that Vdr −/− mice expressed lower intestinal levels of FGF15 than wild type mice, whereas treatment with 1α,25dihydroxy vitamin D 3 increased intestinal FGF15 in wildtype mice 81 . Activation of VDR might also activ ate the FGF19-FGFR4 axis in the intestine and might thus contrib ute to the normalization of bile acid entero hepatic circulation. Activation of VDR upregulates FGF19 expression in the intestine, leading to decreased activ ation of CYP7A1 in the liver and decreased bile acid synthesis in mice -a potentially critical bypass pathway for FXR signal ling, which is downregulated in the intestine in CRC tumours 81 . Moreover, the vitamin D-VDR axis modulates fibrogenesis via epigenetic regulation of the transform ing growth factor β (TGFβ)-SMAD pathway 82 , which can result in a variety of human diseases ranging from autoimmunity to fibrosis and cancer 83 .
Bile acids, liver inflammation and HCC Signalling via bile acid receptors results in the detoxifi cation of bile acids and therefore anti inflammatory effects 84 . In addition to its role in regulating bile acid synthesis and transport, FXR is also a bileacid modulated transcription factor and protective sensor that induces protective cellular responses in hepatic and gastro intestinal tissues and that regulates inflam mation, immune responses and liver regeneration 84, 85 . Dysregulated bile acid synthesis, transport and metabo lism is a common aetiological factor for almost all human liver diseases 36, [86] [87] [88] . In this section, the role of both hepatic FXR and dysbiosis of the gut microbiota in liver inflammation and carcinogenesis is discussed.
Hepatic FXR in liver inflammation. The canalicular export of bile acids from the liver, as discussed previously, is mediated by BSEP; this process is a major determinant of bile acid secretion and is therefore tightly regulated at transcriptional and posttranscriptional levels by several liverenriched transcription factors, including FXR 89 . Sustained inhibition of BSEP expression occurs during hepatic inflammation; decreased FXR expression in response to inflammation reduces the flow of bile and can lead to liver injury 37 . In conditions associated with the hepatic accumulation of bile acids (for example, cholestatic liver injury), activation of FXR also induces the expression of the OSTα-OSTβ complex at the sinu soidal membrane and promotes the efflux of hepatic bile acids to the systemic circulation 90, 91 (FIG. 2b) . Diminished activity of BSEP and OSTα-OSTβ during inflammation directly relate to decreased bile acid dependent activ ation of FXR signalling 37, 89, 90 (FIG. 2b) . In addition, NTCP expression is downregulated at the mRNA and protein levels in response to increased hepatic levels of bile acids and occurs through the FXR-small heterodimer part ner (SHP) pathway 92 , which has an important role in maintain ing bile acid and cholesterol levels by inhibit ing the expression of CYP7A1 (REFS 93, 94) (FIG. 2b) . Therefore, the decrease in hepatic transporter function that occurs as a result of reduced FXR signalling during inflammation leads to increased hepatic bile acid seques tration and sustained inflam mation, which can promote the develop ment of HCC [95] [96] [97] . Bile acids can directly disrupt the plasma membrane and cause activation of protein kinase C (PKC), which in turn activates the p38 mitogen activated protein kinase (p38 MAPK) path way resulting in increased activation of p53 and nuclear factor kappaB (NFκB), ultimately leading to increased apoptosis and inflammation 98 . Activated NFκB is trans located to the nucleus, where it transcribes genes encod ing proinflammatory cytokines, such as TNF, IL1β and IL6 (REFS 99, 100) (FIG. 3) . IL6 can activate the Janus kinase-signal transducer and activ ator of transcription3 (JAK-STAT3) pathway, which leads to decreased apop tosis and the progression of HCC 101 . IL1β activates the phosphoinositide 3kinase (PI3K)-MDM2 pathway to negatively regulate p53, therefore increasing the sur vival of DNAdamaged cells, which might lead to the development of HCC 102 . The NFκB p65 subunit binds directly to FXR and inhibits its transcrip tional activity, promoting the loss of bile acid transporters such as the OSTα-OSTβ complex, increased biosynthesis of bile acids and, ultimately, the accumulation of bile acids in the liver 84 . Membrane pertur bation by bile acids can also activate cytosolic phospholipase A2 (PLA2), causing the release of arachidonic acid from the cell membrane, which can be metabolized by lipoxygenase (LOX) and cyclo oxygenase (COX) to generate ROS in hepato cytes 103, 104 . ROS can directly activ ate NFκB and can also induce direct DNA damage in cells, which might lead to HCC 105 (FIG. 3) .
Mice with wholebody FXR deficiency spontane ously develop liver tumours 94 . In the absence of hepatic FXR, the reexpression of constitutively active FXR in the enterocytes of these Fxrnull mice restored bile acid homeostasis through the activation of the FGF15 axis and protected against the development of HCC 106 . However, hepatocytespecific FXR deficiency (Fxr hep−/− ) in mice did not promote spontaneous liver tumori genesis, suggesting that hepatic FXR deficiency serves only as a tumour initiator and that further increased levels of bile acids (beyond that caused by the loss of FXR alone) are required for tumour development 107 . In addition, it has also been demonstrated that BSEP deficiency -which is caused by inherited muta tions in the BSEPencoding gene, ABCB11, leading to impaired bile salt export from hepatocytes into bile 108 , progressive familial intrahepatic cholestasis and even tually paediatric HCC -is associated with marked increases in intracellular concentrations of bile acids in children 108, 109 . An important determinant of the biological effects of a particular bile acid is its hydrophobicity. The ranking of hydrophobicity, based on chromatographic behaviour, for the major bile acids is LCA, followed by DCA, CDCA, CA, UDCA, αMCA, βMCA and finally ωMCA 33 . Several studies of bileacidinduced hepato cyte injury have indicated that the hydro phobic bile acids LCA, DCA and CDCA are cytotoxic and that the hydrophilic bile acid UDCA, along with its taurine conjugated deriva tive TUDCA, are cyto protective 110 . The intrahepatic accumulation of hydrophobic bile acids such as DCA and CDCA has been proposed as a mech anism of cholestatic liver injury 111 . Increased concentra tions of hydrophobic bile acids caused mito chondrial damage and the disruption of the cell membrane in mouse and human hepatocytes, which ultimately led to the development of HCC via increased levels of ROS and the activation of RAS and NFκB 112 . In particular, NFκB activation induced by TNF in mouse liver tissue inhibited hepatic FXR expression 113 , which subsequently downregulated the expression of SHP -an important tumour suppressor in the develop ment of liver cancer that inhibits cell proliferation and induces apopto sis 114, 115 . In stage I human HCC tissues, FXR expression levels have been shown to be reduced to 40% of the levels in normal liver tissues and are further decreased pro gressively at later stages of the disease 116 . Furthermore, Fxr −/− Shp −/− mice developed liver tumours spontane ously when exposed to chronically elevated intrahepatic concentrations of bile acids 117 . Bile acid accumulation in mouse hepatocytes was sufficient for Hippo path way activation, causing the nuclear translocation of the transcription factor yesassociated protein (YAP), which increased cell proliferation 117 . This induction of proliferation mech anistically involved bileacidinduced overexpression of a key scaffolding protein, Ras GTPase activatinglike protein IQGAP1, which decreases cellcell adhesion via the dissociation of αcatenin from the Ecadherin-βcatenin complex, thus causing the translocation of YAP to the nucleus 117 .
Bile acids and dysbiosis of gut microbiota. Several bile acids, including DCA, LCA, CDCA and TCDCA, have been individually demonstrated to have cyto toxic and cancerpromoting properties 104 . DCA was first shown to be a carcinogen that promoted CRC develop ment in mice in 1940 (REF. 118 ). Administration of a highfat diet (HFD) to mice resulted in changes in the gut microbiota and consequent increases in hepatic levels of DCA 17 ; elevated DCA levels induced . DCA has also been implicated in the development and progression of colon and oesophageal cancer, suggesting that the micro biota also influences colonic and oesophageal carcino genesis through the production of DCA, particularly in the context of obesity 27, 28 . In addition, male mice exposed to lowdose streptozotocin, a chemical used for the destruction of insulinproducing cells and for the generation of type 1 diabetes mellitus phenotypes in mice, in combination with a HFD for 16 weeks devel oped liver tumours 119 ; the gut micro biota profile was markedly altered in mice that developed liver tumours compared with control mice exposed to a HFD alone for 58 weeks 120 , and increased levels of a panel of bile acids -including DCA, TCA, TCDCA and TLCAcollectively contributed to liver tumour development 119 . Thus, sequential steps in a possible mechanism of bile acidinduced liver carcino genesis include a HFD induced alteration of the gut microbiota and increased production of secondary bile acids in the lower intes tine; increased intestinal reabsorp tion and return of bile acids to the liver; increased liver inflammation and consequent down regulation of hepatic FXR, which causes inhibition of several major bile acid transporters (in particular, BSEP); and increased hepatic accumula tion of bile acids, leading to sustained hepatocyte DNA damage, apoptosis and inflammation. In the gastro intestinal tract, disrupted enterohepatic circulation of Figure 3 | Bile acid-induced hepatic inflammation and carcinogenesis. Due to their lipophilic, detergent properties, bile acids (BAs) can directly disrupt the plasma membrane and cause activation of protein kinase C (PKC), which then activates the p38 mitogen-activated protein kinase (p38 MAPK) pathway. The resultant activation of p53 and nuclear factor kappa-B (NF-κB) lead to the induction of apoptosis and increased inflammation. Activated NF-κB translocates to the nucleus and promotes the transcription of genes that encode pro-inflammatory cytokines such as TNF, IL-1β and IL-6, which can positively regulate NF-κB activation and thus promote a continued cycle of inflammation. IL-6 also activates the Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) pathway, which leads to decreased apoptosis and the progression of hepatocellular carcinoma (HCC) 101 . IL-1β also activates the phosphoinositide 3-kinase (PI3K)-MDM2 pathway to negatively regulate p53, thus increasing the survival of DNA-damaged cells through reduced apoptosis, which might lead to HCC 102 . The NF-κB p65 subunit has also been shown to bind directly to farnesoid X receptor (FXR) and inhibit its transcriptional activity, resulting in reduced expression of bile acid transporters (such as organic solute transporter subunit α (OSTα), OSTβ, bile salt export pump (BSEP), multidrug resistance-associated protein 2 (MRP2), multidrug resistance protein (MDR2) and MDR3), which leads to decreased bile acid efflux and cholestasis and increased biosynthesis of bile acids 84 . Inhibition of FXR transcription collectively leads to increased levels of bile acids in the liver, which causes inflammation that can lead to HCC. Membrane perturbation by bile acids can also activate phospholipase A2 (PLA2), causing the release of arachidonic acid (AA) from the cell membrane, which can be metabolized by cyclooxygenase (COX) and lipoxygenase (LOX) to generate reactive oxygen species (ROS) in hepatocytes and, consequently, induce DNA damage 103, 104 . ROS can directly activate NF-κB and can also induce direct DNA damage in cells, which might lead to HCC 105 . 86 . The downregulation of these target genes leads to reduced transport of bile acids from enterocytes back into the portal vein via IBABP and the OSTα-OSTβ complex 84 (FIG. 2b) , resulting in bile acid accumulation in the intestinal mucosa.
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Patients with liver disorders such as fatty liver dis ease, fibrosis, cirrhosis and HCC often exhibit gut dys biosis characterized by a major elevation of aerobic, proinflammatory, BSHrich bacteria of the genera Enterobacter, Enterococcus and Clostridium, which are capable of producing increased amounts of second ary bile acids 51 . Conversely, individuals with intesti nal conditions, such as IBD, often have gut dys biosis characterized by diminished microbial diversity and a decreased abundance of bacteria of the phylum Firmi cutes. Faecali bacterium prausnitzii is particularly under represented, which leads to reduced levels of second ary bile acids and elevated levels of conjugated bile acids in the intestine [121] [122] [123] . These microbiota induced changes in bile acid profiles might therefore result in diminished FXR activity, the downregulation of the expression of hepatic BSEP, hepatic and intestinal OSTα-OSTβ complexes and, consequently, increased intracellular retention of bile acids in hepatocytes and intestinal mucosa 84, 124 (FIG. 2b) . In addition, modifying gut microbiota profiles using probiotics increased faecal excretion of bile acids and promoted hepatic bile acid synthesis in mice, the mechanism of which involved decreased bile acid re absorption from the ileum and repression of the enterohepatic FXR-FGF15 axis 125 , which suggests that dysbiosis and abnormal bile acid metabolism can be reversed with probiotics. Thus, bile acid and gut microbiota profiles influence each other and, when disrupted, jointly produce a gastrointestinal disease phenotype.
Bile acids, colon inflammation and CRC
In addition to the effect of the hepatic accumulation of bile acids in liver carcinogenesis, mounting evidence suggests that patients who are diagnosed with colonic carcinomas who consume a Western diet (high in satur ated fats, red meat and processed carbohydrates) display elevated levels of faecal secondary bile acids, mostly DCA and LCA 126, 127 . Elevated levels of secondary bile acids exert detrimental effects on the architecture and function of the colonic epithelium through multiple mechanisms, including oxidative damage to DNA, inflammation, activation of NFκB and increased cell proliferation 127 . Accordingly, bile acids have been con sidered tumourpromoting factors in the development of CRC 28, 103 . In this section, the bile acid dependent action of TGR5 and the links between bile acids, inflammation and CRC will be discussed.
Activation of TGR5 in macrophages.
Chronic or acute inflammatory conditions, such as Crohn's disease or ulcerative colitis, are characterized by activ ation of the innate immune system and dysregulated pro inflammatory and antiinflammatory cytokine secre tion 128 . Macrophages are major regulators of cytokine production in the gastrointestinal tract; their actions here are primarily through the activation of bile acidresponsive, membranebound TGR5. Bile acid dependent activation of TGR5 inhibited the activation of NFκB induced by lipopolysaccharide injection in wildtype mice but not in lipopolysaccharideinjected TGR5deficient mice 129 . In addition, a series of elegant imaging studies and bioluminescence resonance energy transfer assays showed that TGR5 remains membrane bound and accumulates in lipid rafts in response to treatment with DCA, TLCA and the selective TGR5 agonists oleanolic acid and 3(2chlorophenyl)N (4chloro phenyl)N,5dimethylisoxazole4carboxa mide in HEK293 cells transfected with TGR5 and in NCM460 colonocytes that endogenously express TGR5 (REF. 129 ). In the lipid rafts, TGR5 can transactivate the epidermal growth factor receptor (EGFR) 130 (FIG. 4) .
Although the role of TGR5 in gastrointestinal carcino genesis is unclear, strong immunohistochemical staining of TGR5 was reported in 12% of cases of human intestinal metaplasia 131 . There are two types of tumour associated macrophages: M1 macrophages, which are proinflammatory, and M2 macrophages, which are antiinflammatory and immuno suppressive 132, 133 . The M1 phenotype is character ized by the produc tion of proinflammatory cytokines, such as IL1β, IL6, IL12, IL23 and TNF, that collectively activate type 17 T helper (T H 17) and type 1 T helper (T H 1) cells 134 . IL12 is required to induce the production of IFNγ in M1 macro phages to activate T H 1 cells 134 . M2 macro phages are immunosuppressive and mainly prod uce IL10, which induces the activ ation of regulatory T (T reg ) cells 132 . An M2like macro phage pheno type, an inter mediate form, is induced in response to TGR5 activation by the TGR5 agonist INT767 (REF. 135) and is defined by an increased production of IL10, which causes immuno suppression and further differentiation of M2like macrophages to the M2 state 136 . However, the bileaciddependent activ ation of TGR5 in macro phages cannot completely switch the polarization of a macrophage from the M1 to the M2 state. Instead, bileacidactivated TGR5 induces a 'mixed phenotype' macro phage, whereby the immunosuppressive M2 pheno type predomin ates, as evidenced by an increase in the IL10:IL12 synthesis ratio 137 . Depending on the polarization state of the macrophage, TGR5 activ ation can promote pro inflammatory responses (in M1 macro phages) or antiinflammatory responses (in M2 macro phages) that are immuno suppressive in the context of CRC (FIG. 4) . The major pro inflammatory responses that occur following TGR5 activation in M1 macrophages include increased activation of MYC, which induces apoptosis, proliferation and inflam mation in macro phages in response to surrounding DNAdamaged cells, and NFκB activation, which stimulates the production of proinflammatory cytokines, such as IL6 and TNF, that promote inflammation and inactiv ate FXR 137 . The major antiinflammatory, immuno suppressive response that results from TGR5 activation in M2 macro phages is the production of IL10, which decreases the produc tion of pro inflammatory cytokines such as TNF, IFNβ, and IL6, increases TGFβ expression and increases T reg cell populations, which decrease the activities of T H 17 and T H 1 cells 71, 138 . Thus, bile acid-TGR5 signal ling controls the intricate balance between the prod uction of proinflammatory and antiinflammatory cytokines in the intestine. IL10 induces the differen tiation of T cells into immunosuppressive T reg cells, and IL12 promotes the differentiation of T cells into pro inflammatory T H 1 cells; therefore, the IL10:IL12 ratio is an indicator of the inflammatory status of the intestinal mucosa 139, 140 (FIG. 4) .
Bile acid dysregulation in the development of CRC. Bile acids influence the intestinal environment by controlling the growth and maintenance of commensal micro biota, maintaining barrier integrity and modulating the immune system 141, 142 . The control of intestinal inflam mation through activation of intestinal FXR in response to secondary bile acids, which passively diffuse into enterocytes, has an important role in the normal physio logical function of the colon, where the deconjugation and dehydroxylation of bile acids occurs 38 . Evidence for the influence of commensal bacteria in bile acid synthesis originated in vivo; mice that were raised in the absence of commensal bacteria or that were treated with antibiotics to deplete commensal microbiota produced decreased The M1 macrophage phenotype is pro-inflammatory, and the M2 phenotype is immunosuppressive. Although bile acids (BAs) are not able to induce complete macrophage polarization to either the M1 or M2 phenotype, they have been shown to activate G protein-coupled bile acid receptor 1 (TGR5) and produce a 'mixed phenotype' that exhibits dominant immunosuppressive behaviour as evidenced by an increased IL-10:IL-12 ratio 137 . In response to BAs, TGR5 can activate both the adenyl cyclase-cAMP and epidermal growth factor receptor (EGFR)-SRC kinase (SRC) pathways 129 . In the pro-inflammatory M1-like pathways (dotted arrows), TGR5-dependent transactivation of EGFR can induce pro-inflammatory signalling via activation of SRC, which in turn activates extracellular signal-regulated kinase 1/2 (ERK1/2) and protein kinase C (PKC) 129 . This transactivation has been shown to occur when EGFR and a relevant G-protein coupled receptor (GPCR) such as TGR5 coexist side by side in a lipid raft (signified by cholesterol and sphingolipid). Upon TGR5 activation, metalloproteinase-dependent cleavage of the EGFR ligand heparin-binding EGR (HB-EGF) occurs, which activates the EGFR-SRC pathway 208 . TGR5-dependent activation of PKC results in the activation of nuclear factor kappa-B (NF-κB), which causes increased expression of the pro-inflammatory cytokines IL-1β, IL-6 and TNF, along with further autocrine activation of ERK1/2 and continued cycles of pro-inflammatory signalling. SRC-dependent activation of ERK1/2 in the M1-like phenotype results in increased expression of MYC which increases cell apoptosis 209 . Pro-inflammatory M1-like signalling also regulates innate immunity via the pro-inflammatory cytokines it produces, specifically by increasing the activation of pro-inflammatory responsive type 17 T helper (T H 17) cells (in response to increased IL-1β, IL-6 levels) and T H 1 cells (in response to increased IL-12, IFNγ levels) with concurrent suppression of immunosuppressive T regulatory (T reg ) cells (in response to decreased IL-10 levels) 137 . The pro-inflammatory M1-like phenotype is not dominant during BA-dependent activation of TGR5. Concomitantly, SRC activation also activates signal transducer and activator of transcription 3 (STAT3), which promotes anti-inflammatory M2-like effects (solid arrows) including decreased activation of T H 17 and T H 1 cells, decreased production of TNF, IFNβ, IL-6 and IL-12 and increased production of IL-10 and transforming growth factor β (TGFβ), which corresponds with an increase in the IL-10:IL-12 ratio 71, 138 . BA-activated TGR5 also activates the cAMP pathway independently from EGFR transactivation; cAMP activates protein kinase A (PKA), which leads to the upregulation of cAMP response element binding protein (CREB) expression and activity. FOS, an important target gene product of CREB activity, binds to the p65 subunit of activated NF-κB to inhibit its translocation to the nucleus, representing an anti-inflammatory effect of TGR5. Another important target gene product of CREB activity is IL-10, which exerts immunosuppressive and therefore anti-inflammatory effects 71, 137, 138 . G αs , G protein alpha-s; MMP, matrix metalloproteinase; ROS, reactive oxygen species. faecal levels of secondary bile acids and increased fae cal levels of conjugated bile acids compared with their conventional counterparts that were raised with normal commensal bacterial profiles in their guts 143, 144 . A study of human faecal samples revealed a substantial decrease in abundance of bacteria from the phylum Firmicutes, a marked decrease in the F. prausntizii:E. coli ratio, con siderably higher levels of conjugated bile acids and lower levels of secondary bile acids in patients with active IBD than in healthy individuals 144 . Interestingly, increased amounts of 3OHsulfated secondary bile acids were also detected in patients with active IBD. The sulfation of hepatic bile acids increases their hydrophilicity, therefore reducing their cytotoxicity and enhancing their excre tion in faeces and urine compared with unsulfated bile acids 145 . Thus, sulfation is an important mechanism of bile acid detoxification and homeostasis in the gastro intestinal tract. However, the sulfation of hydrophobic secondary bile acids hampers their ability to activate the antiinflammatory effector FXR 144, 146 . In patients with IBD, the presence of high levels of sulfated bile acids in faeces also implies that there might be a reduced abun dance of specific microbiota in the gut that are capable of desulfating sulfonated bile acids, such as members of the genera Clostridium, Fusobacterium, Peptococcus and Pseudomonas 147 . Collectively, gut dysbiosis can result in a diminished ability of the microbiota to produce unconju gated and secondary bile acids, which are high affinity ligands for FXR activation, as well a reduced abil ity to promote the sulfation of these bile acids to prevent FXR activation.
In addition, many of the bacterial species of the phy lum Firmicutes (for example, Clostridium cluster XIVa bacteria such as Eubacterium rectale and Roseburia spp.) produce butyrate 148 , and a decreased abundance of these bacteria was observed in patients with CRC 149 .
In vitro studies showed that butyrate can inhibit colo rectal carcino genesis by suppressing the growth of tumour cells, inducing differentiation and apoptosis and inhibiting cell proliferation 150, 151 . Moreover, there is an inverse relationship between the levels of butyrate in the human colon and the incidence of CRC 152, 153 , possibly as a result of the reduced capacity of gut microbiota from patients with CRC to produce butyrate 86 . Bacteria from Clostridium cluster XIVa have also been reported to produce secondary bile acids via the 7αdehydroxylation of primary bile acids 38 . Decreased levels of faecal second ary bile acids were observed in patients with IBD compared with the levels in healthy individ uals 144 ; this effect was due to a decrease in the abundance of bacteria of the phylum Firmicutes (for example, Clostridium spp.), which contributed to the loss of the antiinflammatory effects of secondary bile acids on intestinal epithelial cells, thus enhancing chronic inflam mation. Although the observations regarding the loss of butyrateproducing bacteria 86 and the loss of second ary bile acid producing (BSHrich) bacteria in patients with IBD 38 were made separ ately, the butyrate producing bacteria and bile acidproducing bacteria overlap to some extent, and both are depleted during chronic inflammation of the gastrointestinal tract 38, 51, 144, 149 .
Inflammation promotes the development of IBD and its progression to CRC 113, 154 . Pharmacological activ ation of intestinal FXR reduced inflammation and preserved intestinal barrier function in two established mouse models of experimental colitis induced by dextran sodium sulfate and trinitrobenzenesulfonic acid 84 . The FXR agonist obeticholic acid reduced the loss of goblet cells, lowered inflammatory immune cell infiltrate levels and decreased the permeability of the intestinal epithelium in both models. In addition, obeticholic acid decreased the expression of proinflammatory genes, including IL1β, IL6, and CC motif chemokine 2 (CCL2). However, FXRnull mice did not show improvements in colitis with obeticholic acid treatment 84 . Mechanistically, the antiinflammatory effect of FXR agonism resulted from the inhibition of NFκB activation 84, 155 . By con trast, the inhibition of FXR activity by TNF and IL1β, which are upregulated in response to NFκB activ ation, reduced the transcription of FXR target genes 84 . Furthermore, the p65 subunit of activated NFκB was found to interact with FXR directly. Therefore, there are bile acidmediated bidirectional interactions between FXR and components of the inflammation process 156 . Overall, unconjugated bile acids, which are detrimental to hepatocytes at high concentrations, are important for controlling microbial populations in the gut, activat ing intestinal FXR and modulating innate immunity to preserve intestinal barrier function 84, 157 . The pathogenesis of CRC is considered a multistep process that often includes a sequence of cell mutations during the progression from adenoma to carcinoma 158 . The most common mutations in CRC are in the genes encoding adenomatous polyposis coli (APC), KRAS, p53, PI3K and TGFβ 159 (FIG. 5) . Enteral bacterial species that are most frequently associated with CRC include F. nucle atum, colibactinproducing E. coli and B. fragilis, all of which can activate the WNT-βcatenin signalling path way 160 . Interestingly, FXR expression has been found to be decreased at the mRNA level in colonic polyps and to an even greater degree in colonic adenocarcinoma 161 . In normal mouse intestinal tissues, FXR mRNA expres sion was highest in fully differentiated epithelial cells at the apical surface, and FXRdeficient mice had compro mised intestinal barriers, with increased infiltration of immune cells 161 . Consistent with these findings, progres sive decreases in FXR mRNA expression were reported from early to advanced stages of human colitis associated neoplasia, and FXR expression was undetectable in four CRC cell lines 162, 163 . Immunohistochemical evaluation of 159 stage I-IV CRC samples, 32 polyps and 238 nor mal samples revealed a loss of FXR expression in the majority (94%) of CRC samples and markedly reduced FXR expression in precancerous polyps compared with expression in normal colon tissue samples 164 . The inci dence of intestinal cancer is also associated with FXR expression; the ileum, which normally has a higher level of FXR expression than the distal colon, has a lower cancer incidence than the distal colon 164, 165 . The loss of FXR expression in CRC has been hypoth esized to be due to the hypermethylation of the FXR pro moter 163 . However, the presence of hypermethylation was found to depend on the CRC cell line studied; treatment with the DNA methyltransferase antagonist 5azacytidine, which induces DNA hypomethylation, caused dosedependent increases in FXR mRNA levels in HCT116 and SW480 cell lines but not in Caco2 and HT29 cell lines. Two mechanisms for FXR silencing have been proposed in human CRC: methylation of the FXR promoter in microsatellite instability (MSI) high tumours and activation of KRAS signalling in MSIlow tumours 164 . In studies of obesityrelated CRC, a HFD increased the risk of CRC in humans 152 . In addition, Fxr −/− Apc min/+ mice -which are susceptible to CRC -exhibited an expanded bile acid pool resulting from decreased negative regulation of the FXR-FGF15 axis 162, 166 . The increased risk of CRC in response to a HFD might be due to the increased production of secondary bile acids in the colon. Indeed, the overstimulation of bile acid dis charge into the intestine in response to a HFD increases the production of secondary bile acids, which function as tumour promoters 167 . The hydrophobicity of DCA causes membrane perturbations that activate PKC and NADPH oxidase, which induce the downstream activ ation of NFκB 168 (FIG. 5) . Such membrane perturbations also facilitate the release of arachidonic acid, which can be metabolized by LOX and COX, to generate ROS and promote the consequent induction of DNA damage 168, 169 . DCA also induces βcatenin signalling and increases . Expression of MYC increases cell proliferation and stemness. Activation of EGFR also leads to the upregulation of cyclooxygenase (COX) and lipoxygenase (LOX), which promote the production of reactive oxygen species (ROS). BAs can disrupt the plasma membrane to release arachidonic acid (AA) into the cytoplasm where it is rapidly used as a substrate for the production of ROS by COX and LOX 168, 169 . NADPH oxidase can be stimulated by bile acids to further increase ROS production 169 . In the enterocyte, ROS can cause DNA damage and inflammation, leading to upregulated expression of the pro-inflammatory cytokine IL-1β 169 . All these events contribute to the development and progression of CRC. Perturbation of the plasma membrane by bile acids also activates protein kinase C (PKC), which subsequently activates p38 mitogen-activated protein kinase (p38 MAPK) and nuclear factor-kappa B (NF-κB). Activated NF-κB translocates into the nucleus, where it promotes the transcription of IL1B. IL-1β can then signal in an autocrine and paracrine fashion to activate the phosphatidylinositol 3-kinase (PI3K)-MDM2 axis, which results in blockage of p53 activity. Decreased p53 activity leads to decreased apoptosis and increased survival of DNA-damaged cells, contributing to the potential development of CRC 103, 172 . Through unknown mechanisms, bile acids also stimulate the binding of WNT to the low-density lipoprotein receptor-related protein (LRP)-frizzled receptor (FZ)-E-cadherin-β-catenin complex, which causes the release of β-catenin from E-cadherin and into the cytoplasm where it translocates to the nucleus and stimulates transcription factors such as T cell factor (TCF)-lymphoid enhancer factor (LEF) to increase cell proliferation and cell stemness, contributing to the development and progression of CRC 
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Enterocyte the degradation of p53 (FIG. 5) , which together result in increased cell proliferation and invasiveness of colon cancer cells 170 . However, new evidence suggests that HFDinduced increases in intestinal levels of secondary bile acids might be a transient process and that unconju gated bile acids (including DCA) might be gradually depleted from the intestine under chronic inflamma tory conditions, presumably as a result of the depletion of BSHrich bacteria in the intestine 144, 171 . In addition, treatment with cholestyramine, a bile acid sequestrant that binds all bile acids, did not modify the tumour susceptibility of Fxr −/− Apc min/+ mice 166 . Secondary bile acids help to maintain a viable epithe lial layer of cells by inducing apoptosis and promoting cell turnover. Thus, exposure to high levels of secondary bile acids in response to a HFD intervention and then to gradually decreasing levels of secondary bile acids resulting from inflammation might have two important consequences: increased apoptosis of fully differenti ated epithelial cells at the apical surface that express high levels of FXR and continued renewal and increased selective growth of less differentiated cells that are resist ant to apoptosis and express low levels of FXR 162, 172 . Together, the carcinogenic effects of intestinal bile acids on the development and progression of CRC might be different from those in HCC. The gradual depletion of unconjugated secondary bile acids in response to gut dysbiosis, and subsequently the emergence of less differentiated and highly proliferative colon epithelial cells with a loss of FXR function, might be key factors contributing to colorectal carcinogenesis.
Targeting bile acid signalling
Inflammation promotes the development of both CRC and HCC, and patients with inflammatory diseases such as IBD are more likely to develop gastro intestinal cancer 173 . Based on the discussions outlined in this Review, the most important therapeutic considerations for the treatment of gastrointestinal diseases such as HCC and CRC are restoring FXR signalling by correct ing gut dysbiosis, reestablishing normal enterohepatic circulation of bile acids and controlling inflammation of the gastrointestinal tract. Therapeutic targeting of FXR and TGR5 signalling might be important in restoring normal enterohepatic circulation and controlling gastro intestinal inflammation. TABLE 1 summarizes the pro gress that has been made to date in targeting bile acid signalling in gastrointestinal diseases.
Gut dysbiosis is one of the most probable inducers of IBD 174 . Patients with ulcerative colitis are six times more likely to develop CRC than the general popula tion 175 . Although IBDassociated CRC accounts for only 1-2% of all cases of CRC, IBD with colon involvement is among the top three highrisk conditions for CRC, and CRC accounts for approximately 10-15% of all deaths among patients with IBD 175 . Probiotics -live micro organisms that, when administered in adequate amounts, confer a health benefit to the host 176 -are ingested to normalize the gut microbiota and improve mucosal barrier function through different mech anisms, including the production of SCFAs, which activate GPCRs such as TGR5 on enterocytes and immune cells to increase the synthesis and release of antiinflammatory cytokines (such as IL10) and the levels of T reg cells 177 . A systematic review of 14 studies on patients with Crohn's disease and 21 studies on patients with ulcerative colitis revealed that patients with Crohn's disease who had taken probiotics in conjunction with conventional therapy did not show a substantial clin ical improvement in disease symptoms 178 . However, the addition of probiotics to conventional treatment with mesalamine improved both the induction and mainten ance of remission for patients with ulcerative colitis. A probiotic formulation, VSL#3 (VSL Pharmaceuticals, Italy), also showed promising results for treating mild to moderately severe ulcerative colitis but not for treating Crohn's disease 179, 180 . Bile acid receptors, such as FXR, PXR, CAR and VDR, are therapeutic targets for the treatment of choles tatic liver disease, fatty liver disease, diabetes mellitus, gallstones, obesity and metabolic syndrome 33, 181, 182 . Almost all of the proteins involved in the production, uptake, metabolism and transport of bile acids can alter the size and composition of the bile acid pool and bile acid signalling and thus represent potential thera peutic targets. For example, 24norursodeoxycholic acid (norUDCA), a derivative of UDCA formed by the removal of a methylene group, is more hydrophilic and less toxic than UDCA 66, 183 , is resistant to conjuga tion and can be absorbed by cholangiocytes via passive diffusion 184 . Treatment with norUDCA stimulates the secretion of bicarbonate (HCO 3 − ) from biliary cells, which forms an alkaline (HCO 3 − ) 'umbrella' on the apical cholangio cyte surface, leading to the deprotonation of apolar hydrophobic bile acids, preventing apolar hydro phobic bile acids from entering cholangiocytes and/or hepatocytes 183 . FXR agonists have been developed that have a higher affinity for FXR than endogenous bile acids and are being evaluated as drugs for the clinical manage ment of primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) 185, 186 . Both UDCA therapy and the synthetic FXR agonist PX102 are currently under clinical assessment in phase II and phase III clinical trials, respectively 187 . Obeticholic acid has been approved by the FDA for the treatment of PBC, in combination with UDCA in adults with an inadequate response to UDCA or as monotherapy in adults who are unable to tolerate UDCA 188 . TGR5 agonists have shown promise for the control of inflammation in human cellbased models and animal models of both Crohn's disease and ulcerative colitis 71, 189 ; however, these agents are not being tested in clinical trials. Several TGR5 agonists have been designed to confer specificity for the TGR5 receptor over FXR in the treatment of TGR5mediated disorders, which limits adverse effects linked to an inadvertent activation of FXR 190 . Methylation at the C23 position of endogen ous bile acids promoted selectivity for TGR5 (REF. 191) , which led to the development of INT777, a semi synthetic bile acid 192 derived from CA. Nonsteroidal TGR5 agonists include naturally occurring compounds such as oleanolic acid, which is derived from olive leaves, and synthetic
Primary biliary cholangitis
A type of liver disease caused by damage to the bile ducts in the liver.
Primary sclerosing cholangitis
A chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts.
compounds such as 3aryl4isoxazole carbox amides, which are derived from chemical libraries 189 . Although TGR5 agonists have shown promise in the control of hepatic and gastrointestinal inflammation 71, 189 , addi tional studies are necessary before translation to the clinical setting.
Bileacidbinding resins (or bile acid sequestrants) such as cholestyramine and colestimide have been used to remove bile acids from the intestine via chelation and excretion in faeces. The enterohepatic circulation of bile acids is decreased as a result, leading to increased conversion of cholesterol to bile acids in a compen satory mechanism to maintain bile acid levels 193 . Due to the metabolic interactions between the intestinal bile acid pool and the gut microbiota, the administra tion of bileacidbinding resins might readily alter the composition of intestinal microbial species and might also have thera peutic value in the treatment of gastro intestinal cancers, particularly HCC. Inhibiting entero hepatic bile acid circulation using the ASBT inhibitor SC435 improved both hepatic and systemic symptoms of NAFLD in mice fed a HFD 194 . Another ASBT inhib itor, A4250, ameliorated liver cholestasis and bile duct injury in a mouse model of PSC 195 . The use of intestinal microbial strains that are engin eered to increase the direct consumption of pathogenic metabolites or exogenous chemicals also represents a novel strategy to target the metabolic crosstalk between the liver, bile acids and gut microbiota for the prevention of gastrointestinal cancers. Hyperammonaemia (induced by carbon tetrachloride in rats and by thioacetamide in mice, or constitutive hyperammonaemia) can be effec tively ameliorated in rodent models by the administra tion of a strain of Lactobacillus plantarum genetically engineered to consume ammonia 196 . The ammonia hyperconsuming L. plantarum strain lowered ammonia levels in the blood and faeces and improved the sur vival of hyperammonaemic mice compared with levels in hyperammonaemic mice treated with the wildtype L. plantarum strain. Similarly, L. plantarum 80 (pCBH1), a genetically engineered strain overexpressing BSH, efficiently degraded GDCA and TDCA in vitro, and the oral administration of this strain significantly lowered serum cholesterol levels 197 . Intervention strategies based on the administration of engineered species are advan tageous over other strategies such as antibiotic admin istration based on the modulation of the gut microbiota because genetically engineered microbial strains can be directed specifically to the pathogenic molecule or metabolic pathways of interest, rather than targeting the entire enteral microbial community -a 'silver bullet' approach.
Conclusions
Apart from facilitating the absorption of dietary fats, bile acids act as strong signalling molecules through different nuclear receptors and cell signalling pathways to regulate lipid, glucose and energy metabolism. Research in the past three decades has contributed substantially to our understanding of the mechanisms of bile acid metabo lism and of the pathogenesis of gastrointestinal cancers. In this Review, we discussed the mechanisms of bile acid synthesis, transport and metabolism, and we highlighted the signalling regulation of bile acid synthesis and trans port in normal and disease states. We discussed the mechanistic links between bile acids, the gut microbiota, gastrointestinal inflammation and cancer, with a focus on CRC and HCC. Bile acids, bile acid activated nuclear receptors (such as FXR, PXR, CAR and VDR), and TGR5 are key therapeutic targets for the development of drugs to treat gastrointestinal cancers.
Our knowledge of the functional relevance of the human gut microbiota in gastrointestinal carcino genesis is still in its infancy. With the advent of new profiling tools and strategies, including metagenomics and metabo lomics, we are rapidly gaining mechanistic insights into the metabolic interactions between the gut and the liver and into the signalling pathways that regulate the development of gastrointestinal cancers. Modulation of the gut microbiota and bile acid profile represent novel therapeutic approaches for the treat ment of gastrointestinal cancers, including CRC and HCC; this strategy holds much promise and clearly represents the next frontier for gastrointestinal cancer research. Given the complexity of the processes involved in bile acid signalling, as well as the complex metabolic interactions between the gut microbiota and the host, a systems biology perspective is required to understand the complexities of liver-bile acid-microbiota crosstalk and its influence in gastrointestinal carcinogenesis. The individual components of the liver-bile acid-microbiota axis cannot be isolated, and the successful treatment of gastrointestinal diseases will involve therapeutic interventions that modulate all of these components. Future research to inform the control and prevention of gastro intestinal cancers might include identifying clusters of beneficial commensal microbiota and their critical metabolites, which modulate the inflammation that drives gastrointestinal carcinogenesis. Multifaceted approaches that integrate metagenomic and metabo lomic profiling from wellcharacterized gnotobiotic animal models will be essential in determining the role of microbiota mediated alterations in bile acids in the development of gastrointestinal cancers. In addition, dis tinct profiles of gut microbiota and bile acids have been reported in males and females, and these might contrib ute to the sexbased disparity in liver carcino genesis 198 . A better understanding of the hormonal effects of bile acids on their receptors will reveal opportunities for the prevention and control of gastrointestinal cancers that often exhibit gender differences. The prevention of bile acid toxicity in the intestine and liver by controlling the quantity and types of bile acids that are present will require a greater understanding of the regulation of the pathways involved in the synthesis, transport and metabolism of bile acids.
